

**AMENDMENT**

Kindly amend the application, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

**IN THE SPECIFICATION:**

Kindly amend the specification, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Page 9, lines 18-19, please replace the paragraph thereat as follows:

SEQ ID Nos. 1 and 31 Complete sequence of the CHV ORF1 →  
ORF5 region depicted in Figure 1

Immediately after page 23 and before the first page of claims (page 24), please insert the enclosed pages identified as --Sequence Listing--.

Seq. List,  
Placed before  
Chv.

**IN THE CLAIMS:**

Kindly add new claims 17-49, without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents, as follows:

Sub: D1  
B2  
--17. A recombinant canine herpes virus (CHV) comprising and expressing at least one heterologous nucleotide sequence encoding an antigen selected from the group consisting of canine distemper virus HA, canine distemper virus F, rabies virus G, canine parvovirus VP2, parainfluenza virus type 2 HA, parainfluenza virus type 2 F, *Borrelia burgdorferi* OspA, and *Borrelia burgdorferi* OspB.

18. The recombinant CHV according to claim 17 wherein the at least one heterologous nucleotide sequence is in at least one site selected from the group consisting of ORF3 (SEQ ID NO:4), ORF5 (SEQ ID NO:5), the thymidine kinase gene, and the intergenic region corresponding to genes coding for the large subunit and the small subunit.

19. The recombinant CHV of claim 18 wherein at least one heterologous nucleotide sequence is inserted by simple insertion, or after total or partial deletion of the insertion locus.